PUBLISHER: DelveInsight | PRODUCT CODE: 1184443
PUBLISHER: DelveInsight | PRODUCT CODE: 1184443
DelveInsight's , "Herpes Zoster - Pipeline Insight, 2023" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Herpes zoster (HZ), also called as Shingles, is a neurocutaneous disease that is generally caused by the reactivation of varicella-zoster virus (VZV) from a latent infection of dorsal sensory or cranial nerve ganglia following primary infection with VZV before in life. VZV is a double-stranded DNA herpes virus with a genome that contains at least 70 gene products that can affect cellular immunity of the body.
VZV is explicitly a human virus that belongs to the α-herpes virus family. It is present worldwide and is highly contagious. More than 90% of adults in the United States acquired the disease in childhood, while the majority of children and young adults have been vaccinated with the live virus vaccine.
Herpes zoster is usually less severe in children than younger adults. It is common in people with diminished cell-mediated immunity which includes older people, patients with lymphoma, those receiving chemotherapy or steroids, and people with HIV. People who earlier had chickenpox are at a higher risk for herpes zoster. VZV-induced neuronal destruction, and inflammation causes pain, interferes with day-to-day activities, and diminish the quality of life.
Commonly, the first symptoms are pain and burning. The pain usually occurs on one side of the body and appears in small patches, followed by red rashes. Polymerase chain reaction (PCR) is the primary method for the diagnosis of herpes zoster as it has very high sensitivity and specificity. Direct fluorescent antibody (DFA) and other antigen-detection methods can be used on biopsy material, and eosinophilic nuclear inclusions and are used as a method for diagnosis. Various treatment methods are in use to treat Acute Herpes zoster, such as corticosteroids, adjuvant agents, analgesics, and others. Pharmacotherapy such as topical lidocaine patch, gabapentin, pregabalin, tricyclic antidepressants, and/or opiates are used to treat Postherpetic Neuralgia (PHN) which is associated with chronic pain. Apart from treatment, various Live Attenuated Zoster Vaccines have been developed, such as Zostavax by Merck, and Subunit Adjuvanted Zoster Vaccine, which has been marketed under the name Shingrix by GlaxoSmithKline.
"Herpes Zoster - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes Zoster pipeline landscape is provided which includes the disease overview and Herpes Zoster treatment guidelines. The assessment part of the report embraces, in depth Herpes Zoster commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes Zoster collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Herpes Zoster R&D. The therapies under development are focused on novel approaches to treat/improve Herpes Zoster.
This segment of the Herpes Zoster report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CRV-101 is a next-generation shingles vaccine candidate designed to maximize the CMI protection by combining the gE protein antigen with our proprietary adjuvant. Curevo's CRV-101 is an investigational adjuvanted subunit vaccine for the indication of the prevention of Herpes Zoster in older adults. The adjuvanted subunit vaccine strategy contrasts with traditional approaches using live killed or attenuated viruses. Sub-unit vaccines do not contain virus components and cannot cause infection. The adjuvant component was specifically engineered to produce an optional immune response while using a smaller amount of adjuvant with a targeted structure-function approach. CRV101 is being developed in Phase II stage of development to treat Herpes Zoster.
A varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent herpes zoster caused by the varicella-zoster virus (VZV). The vaccine combines a recombinant antigen, glycoprotein E (VZVgE), and CIA05, an adjuvant system which is a non-toxic LOS-derived substance with optimal immunologic activity. A Phase I clinical trial evaluating the EG-HZ vaccine has been completed.
SIS is developing several 'NCE's for anti-inflammatory indications. ZEP-3 possess a unique, combination of pharmacological activities for the treatment of these clinical areas of research. The unique combination of anti-inflammatory and anti-viral activity, in addition to analgesic activity, gives ZEP-3 an advantage over the existing treatments for Herpes Labialis, which are only based on anti-viral activity (Zovirax). Efficacy studies have shown that ZEP-3 is equally effective both on HSV-1 and HSV-2 for acyclovir-resistant viruses. At the same time, a growing population does not respond to the existing therapy because of acyclovir resistance. The Company's ZEP-3 is not based on steroids, thus giving the company a clear and unique advantage. SIS completed a Phase I clinical study on healthy volunteers. This Phase I was suitable for several indications such as: Herpes Labialis, Herpes Zoster, Atopic Dermatitis and Burns.
This segment of the report provides insights about the different Herpes Zoster drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 18+ key companies which are developing the therapies for Herpes Zoster. The companies which have their Herpes Zoster drug candidates in the most advanced stage, i.e. Phase II include, Curevo Inc.
DelveInsight's report covers around 20+ products under different phases of clinical development like
Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
Products have been categorized under various Molecule types such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Herpes Zoster therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes Zoster drugs.